Literature DB >> 19834062

Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4 activation.

Shahla Abdollahi-Roodsaz1, Leo A B Joosten, Marije I Koenders, Ben T van den Brand, Fons A J van de Loo, Wim B van den Berg.   

Abstract

Toll-like receptors (TLRs) may contribute to the pathogenesis of chronic inflammatory destructive diseases through the recognition of endogenous ligands produced on either inflammation or degeneration of the extracellular matrix. The presence of endogenous TLR agonists has been reported in rheumatoid joints. In the present study, we investigated the significance of TLR2 and TLR4 activation by locally- produced endogenous ligands in the severity of joint inflammation and destruction. Local joint pathology independent of systemic immune activation was induced by overexpression of interleukin (IL)-1 and TNF in naive joints using adenoviral gene transfer. Here, we report that at certain doses, IL-1-induced local joint inflammation, cartilage proteoglycan depletion, and bone erosion are dependent on TLR4 activation, whereas TLR2 activation is not significantly involved. In comparison, tumor necrosis factor alpha-driven joint pathology seemed to be less dependent on TLR2 and TLR4. The severity of IL-1-induced bone erosion and irreversible cartilage destruction was markedly reduced in TLR4(-/-) mice, even though the degree of inflammation was similar, suggesting uncoupled processes. Furthermore, the expression of cathepsin K, a marker for osteoclast activity, induced by IL-1beta was dependent on TLR4. Overexpression of IL-1beta in the joint as well as ex vivo IL-1 stimulation of patellae provoked the release of endogenous TLR4 agonists capable of inducing TLR4-mediated cytokine production. These data emphasize the potential relevance of TLR4 activation in rheumatoid arthritis, particularly with respect to IL-1-mediated joint pathology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19834062      PMCID: PMC2774064          DOI: 10.2353/ajpath.2009.090262

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  56 in total

1.  Reactivation of antigen-induced arthritis in mice by oral administration of lipopolysaccharide.

Authors:  S Yoshino; K Yamaki; S Taneda; R Yanagisawa; H Takano
Journal:  Scand J Immunol       Date:  2005-08       Impact factor: 3.487

2.  Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells.

Authors:  Allan Tsung; Rosemary A Hoffman; Kunihiko Izuishi; Nathan D Critchlow; Atsunori Nakao; Meagan H Chan; Michael T Lotze; David A Geller; Timothy R Billiar
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

3.  Expression of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines interleukin-12 and interleukin-18 via interferon-gamma.

Authors:  Timothy R D J Radstake; Mieke F Roelofs; Yvonne M Jenniskens; Birgitte Oppers-Walgreen; Piet L C M van Riel; Pilar Barrera; Leo A B Joosten; Wim B van den Berg
Journal:  Arthritis Rheum       Date:  2004-12

Review 4.  Mammalian Toll-like receptors: to immunity and beyond.

Authors:  P A Hopkins; S Sriskandan
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

5.  Regulation of lung injury and repair by Toll-like receptors and hyaluronan.

Authors:  Dianhua Jiang; Jiurong Liang; Juan Fan; Shuang Yu; Suping Chen; Yi Luo; Glenn D Prestwich; Marcella M Mascarenhas; Hari G Garg; Deborah A Quinn; Robert J Homer; Daniel R Goldstein; Richard Bucala; Patty J Lee; Ruslan Medzhitov; Paul W Noble
Journal:  Nat Med       Date:  2005-10-23       Impact factor: 53.440

6.  The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells.

Authors:  M F Roelofs; L A B Joosten; S Abdollahi-Roodsaz; A W T van Lieshout; T Sprong; F H van den Hoogen; W B van den Berg; T R D J Radstake
Journal:  Arthritis Rheum       Date:  2005-08

7.  IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation.

Authors:  L A Joosten; M M Helsen; T Saxne; F A van De Loo; D Heinegard; W B van Den Berg
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

8.  The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages.

Authors:  Liliana Schaefer; Andrea Babelova; Eva Kiss; Heinz-J Hausser; Martina Baliova; Miroslava Krzyzankova; Gunther Marsche; Marian F Young; Daniel Mihalik; Martin Götte; Ernst Malle; Roland M Schaefer; Hermann-Josef Gröne
Journal:  J Clin Invest       Date:  2005-07-14       Impact factor: 14.808

9.  Induction by chronic autoimmune arthritis in DBA/1 mice by oral administration of type II collagen and Escherichia coli lipopolysaccharide.

Authors:  K Terato; X J Ye; H Miyahara; M A Cremer; M M Griffiths
Journal:  Br J Rheumatol       Date:  1996-09

10.  Enhanced expression of heat shock protein 70 (hsp70) and heat shock factor 1 (HSF1) activation in rheumatoid arthritis synovial tissue. Differential regulation of hsp70 expression and hsf1 activation in synovial fibroblasts by proinflammatory cytokines, shear stress, and antiinflammatory drugs.

Authors:  G Schett; K Redlich; Q Xu; P Bizan; M Gröger; M Tohidast-Akrad; H Kiener; J Smolen; G Steiner
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

View more
  23 in total

1.  Impact of IL-1 signalling on experimental uveitis and arthritis.

Authors:  Stephen R Planck; April Woods; Jenna S Clowers; Martin J Nicklin; James T Rosenbaum; Holly L Rosenzweig
Journal:  Ann Rheum Dis       Date:  2012-01-20       Impact factor: 19.103

Review 2.  Negative regulation of TLR signaling in myeloid cells--implications for autoimmune diseases.

Authors:  Jessica A Hamerman; Jessica Pottle; Minjian Ni; Yantao He; Zhong-Yin Zhang; Jane H Buckner
Journal:  Immunol Rev       Date:  2016-01       Impact factor: 12.988

Review 3.  Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.

Authors:  Jamie Campbell; David Lowe; Matthew A Sleeman
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 4.  Toll-like receptors and chronic inflammation in rheumatic diseases: new developments.

Authors:  Leo A B Joosten; Shahla Abdollahi-Roodsaz; Charles A Dinarello; Luke O'Neill; Mihai G Netea
Journal:  Nat Rev Rheumatol       Date:  2016-05-12       Impact factor: 20.543

Review 5.  TLRs, future potential therapeutic targets for RA.

Authors:  Hatem A Elshabrawy; Abdul E Essani; Zoltán Szekanecz; David A Fox; Shiva Shahrara
Journal:  Autoimmun Rev       Date:  2016-12-15       Impact factor: 9.754

6.  Atopic asthmatic subjects but not atopic subjects without asthma have enhanced inflammatory response to ozone.

Authors:  Michelle L Hernandez; John C Lay; Bradford Harris; Charles R Esther; W June Brickey; Philip A Bromberg; David Diaz-Sanchez; Robert B Devlin; Steven R Kleeberger; Neil E Alexis; David B Peden
Journal:  J Allergy Clin Immunol       Date:  2010-09       Impact factor: 10.793

7.  Epithelial regulation of mesenchymal tissue behavior.

Authors:  Corrie L Gallant-Behm; Pan Du; Simon M Lin; Philip T Marucha; Luisa A DiPietro; Thomas A Mustoe
Journal:  J Invest Dermatol       Date:  2011-01-13       Impact factor: 8.551

8.  Autoimmunity in Coxsackievirus B3 induced myocarditis: role of estrogen in suppressing autoimmunity.

Authors: 
Journal:  Future Virol       Date:  2010-05-01       Impact factor: 1.831

9.  TLR2 deletion promotes arthritis through reduction of IL-10.

Authors:  Qi-Quan Huang; Renee E Koessler; Robert Birkett; Harris Perlman; Lianping Xing; Richard M Pope
Journal:  J Leukoc Biol       Date:  2013-02-27       Impact factor: 4.962

10.  The Chondroprotective Role of Erythromycin in a Murine Joint Destruction Model.

Authors:  Tomoya Uchimura; Andrea T Foote; David C Markel; Weiping Ren; Li Zeng
Journal:  Cartilage       Date:  2016-02-17       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.